Table 4 Clinical data of Standard-Intermediate and High risk groups according to CD56 expression
From: Evaluating the prognostic value of CD56 in pediatric acute myeloid leukemia
Patients data | Standard-Intermediate risk | High risk | ||||
|---|---|---|---|---|---|---|
CD56(+) (n = 49) | CD56(−) (n = 68) | p | CD56(+) (n = 13) | CD56(−) (n = 15) | P | |
Age(Months) | ||||||
Median(range) | 67(11–176) | 87(8–168) | 0.247 | 22(10–141) | 38(8–162) | 0.274 |
≤ 36 months(n,%) | 14(28.6%) | 11(16.2%) | 0.107 | 8(61.5%) | 8(53.3%) | 0.476 |
> 36 months(n,%) | 35(71.4%) | 57(83.8%) | 5(38.5%) | 7(46.7%) | ||
Sex(n,%) | ||||||
Male | 24(49.0%) | 23(33.8%) | 0.099 | 6(46.2%) | 7 (46.7%) | 1.000 |
Female | 25(51.0%) | 45(66.2%) | 7(53.8%) | 8 (53.3%) | ||
WBC at diagnosis (n,%) | ||||||
< 50 × 109/L | 32(65.3%) | 44(64.7%) | 0.946 | 12(92.3%) | 10(66.7%) | 0.173 |
≥ 50 × 109/L | 17(34.7%) | 24(35.3%) | 1(7.7%) | 5(33.3%) | ||
Extramedullary infiltration(n,%) | ||||||
Yes | 6(12.2%) | 7(10.3%) | 0.740 | 0(0.0%) | 0(0.0%) | – |
No | 43(87.8%) | 61(89.7%) | 13(100%) | 15(100.0%) | ||
AML1-ETO(n,%) | ||||||
Yes(n) | 17(34.7%) | 21(30.9%) | 0.644 | 4(30.8%) | 3(20.0%) | 0.670 |
No(n) | 32(65.3%) | 47(69.1%) | 9(69.2.9%) | 12(80.0%) | ||
FLT3-ITD (n,%) | ||||||
Yes | 3(6.1%) | 6(8.8%) | 0.850 | 1(7.7%) | 3(20.0%) | 0.600 |
No | 46(93.9%) | 62(91.2%) | 12(92.3%) | 12(80.0%) | ||
Complex karyotype(n,%) | ||||||
Yes | 4(8.2%) | 1(1.5%) | 0.160 | 5 (38.5%) | 8 (53.3%) | 0.476 |
No | 45(91.8%) | 67(98.5%) | 8 (61.5%) | 7 (46.7%) | ||
Clinical outcome (n,%) | ||||||
CR1a | 48(98.0%) | 67(98.5%) | 1.000 | 3(23.1%) | 8 (53.3%) | 0.137 |
CR2b | 49(100.0%) | 68(100.0%) | – | 5(38.5%) | 12 (80.0%) | 0.050 |
Resistant | 0 | 0 | – | 8 (61.5%) | 3 (20.0%) | 0.050 |
Relapse | 3(6.1%) | 5(7.4%) | 1.000 | 4(30.8%) | 0 (0.0%) | 0.035 |
Death | 5(10.2%) | 9(13.2%) | 0.618 | 8(61.5%) | 2 (13.3%) | 0.016 |